Phil Taylor is a biomedical scientist by training and has worked as a reporter, editor, and publisher in the healthcare, medical, and biopharmaceutical sectors for more than 30 years.
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
Biogen has given an update on the rollout of its Eisai-partnered Alzheimer’s disease therapy Leqembi alongside its first-quarter results, showing that while the drug’s tak
Any new company wanting to make waves in applying artificial intelligence to drug discovery will need deep pockets and a top-tier science and management team – and startup
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.
